Quick Summary Key Result: Intellia Therapeutics reports up to an 81% reduction in angioedema attacks for high-dose recipients in its Phase 2 trial. Therapeutic Potential:
Quick Summary Trial Outcome: Boston Scientific’s Acurate neo2 transcatheter aortic valve replacement (TAVR) system missed its primary endpoint in a critical trial. Comparison Results: Acurate
Quick Summary Deal Value: Biogen partners with Neomorph in a deal worth up to $1.45 billion. Focus: Development of molecular glue degraders for cancer and
Quick Summary Deal Value: AbbVie acquires Aliada Therapeutics for $1.4 billion. Strategic Focus: Expands AbbVie’s central nervous system (CNS) and oncology capabilities. Therapeutic Goals: Strengthening
Quick Summary Device Count: Over 950 AI-enabled medical devices have been cleared by the FDA, with radiology devices comprising the majority. FDA Pathway: Most devices
Quick Summary Contract Value: $1.24 billion—the largest single contract for Samsung Biologics to date. Client: An Asia-based pharmaceutical company. Production Location: Songdo, South Korea, at
Quick Summary Investment Amount: Agomab Therapeutics raised $89 million in Series D financing. Key Backers: Led by new investors Sanofi and Invus, with participation from
Pfizer’s Respiratory Syncytial Virus (RSV) vaccine, Abrysvo, recently received FDA approval for use in adults aged 18 to 59 who are at increased risk for
Merck & Co. has acquired Modifi Biosciences, a precision oncology biotech, in a deal that includes a $30 million upfront payment and potential milestones totaling
Novartis’ €2.7 Billion Investment in MorphoSys Hits Setback as Safety Signal Delays Key Drug Filing Novartis’ recent acquisition of MorphoSys aimed to bring promising therapies
